These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 4994940)

  • 1. [Survival of tuberculous bacilli in combined treatments including rifampicin].
    Kreis B; Pretet S
    Rev Tuberc Pneumol (Paris); 1970; 34(3):429-33. PubMed ID: 4994940
    [No Abstract]   [Full Text] [Related]  

  • 2. [Activity of the second-line preparations, ethambutol and rifampin, in experimental tuberculosis caused by Mycobacterium tuberculosis highly resistant to basic tuberculostatics].
    Golyshevskaia VI; El'shanskaia MP
    Probl Tuberk; 1973; 51(12):60-4. PubMed ID: 4205666
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary and acquired drug resistance in Mycobacterium tuberculosis strains in western region of Libyan Arab Jamahiriya.
    Elghoul MT; Joshi RM; Rizghalla T
    Trop Geogr Med; 1989 Oct; 41(4):304-8. PubMed ID: 2517554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental in-vitro and in-vivo studies of the antibacterial effect of rifampicin and ethambutol].
    Kozulicyna TI; Korotajev GA
    G Ital Chemioter; 1972; 19(2):7-10. PubMed ID: 4199030
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dynamics of rifampicin and ethambutol resistance of strains of Koch bacilli isolated from patients with pulmonary tuberculosis 1973-1981].
    Ionescu C; Timoşca S; Petreanu V; Petreanu C; Georgescu M; Martinescu T
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1982; 31(4):315-20. PubMed ID: 6304845
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical significance of drug resistance of tuberculosis mycobacteria and L-forms].
    Golanov VS; Bogdalova VE; Andreev LP; Losin EI; Ushakova AG; Meshcheriakov VG; Bondin SV
    Probl Tuberk; 1991; (12):27-8. PubMed ID: 1803368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bacteriologic negation and anatomic development in pulmonary specimens after rifampicin treatment of less than 10 months (10 cases)].
    Constans P; Parrot R; Coury C
    Rev Tuberc Pneumol (Paris); 1970 Jun; 34(4):511-8. PubMed ID: 4994883
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002).
    Negi SS; Gupta S; Lal S
    J Commun Dis; 2003 Jun; 35(2):74-81. PubMed ID: 15562952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin.
    Jenne JW; Beggs WH
    Am Rev Respir Dis; 1973 Jun; 107(6):1013-21. PubMed ID: 4197230
    [No Abstract]   [Full Text] [Related]  

  • 10. Short-course treatment regimens for patients with tuberculosis.
    Dutt AK; Stead WW
    Arch Intern Med; 1980 Jun; 140(6):827-9. PubMed ID: 6770770
    [No Abstract]   [Full Text] [Related]  

  • 11. Rifampicin and ethambutol in the treatment of drug resistant and far advanced pulmonary tuberculosis (with a note on capreomycin).
    Pines A; Raafat H; Siddiqui GM
    J Ir Med Assoc; 1970 Mar; 63(393):82-5. PubMed ID: 4984340
    [No Abstract]   [Full Text] [Related]  

  • 12. [Question of bactericidal effect of a combination of maximally tolerable doses of INH, Myambutol and Rifadin on experimental tuberculosis].
    Djurisić M; Davidović C; Leposavić M; Jovancvić M; Marković L; Popović S
    Plucne Bolesti Tuberk; 1973; 25(3):251-6. PubMed ID: 4210992
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.
    Toungoussova S; Caugant DA; Sandven P; Mariandyshev AO; Bjune G
    Int J Tuberc Lung Dis; 2002 May; 6(5):406-14. PubMed ID: 12019916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental and clinical studies of rifampicin in tuberculosis.
    Konno K; Oizumi K; Hayashi I; Oka S
    Sci Rep Res Inst Tohoku Univ Med; 1970 Dec; 17(3):110-20. PubMed ID: 5004309
    [No Abstract]   [Full Text] [Related]  

  • 15. A study of primary drug resistance in pulmonary tuberculosis in west Malaysia 1984-1987.
    Jalleh RD; Kuppusamy I; Soshila R; Aziah AM; Faridza MY
    Med J Malaysia; 1993 Jun; 48(2):113-6. PubMed ID: 8350784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Critical concentration for definition of rifampicin resistance of tubercle bacilli].
    Tsukamura M
    Kekkaku; 1972 May; 47(5):113-9. PubMed ID: 4625369
    [No Abstract]   [Full Text] [Related]  

  • 17. [Changes in the bacteriologic findings in patients treated with rifomycin, alone or associated with other drugs].
    Delli Veneri F; Centrella G; Stefanelli R
    Arch Tisiol Mal Appar Respir; 1968 May; 23(5):387-98. PubMed ID: 4979475
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary drug resistance: a continuing study of drug resistance in tuberculosis in a veteran population within the United States. VII. September 1965 to September 1969.
    Hobby GL; Johnson PM; Boytar-Papirnyik V
    Am Rev Respir Dis; 1970 Sep; 102(3):347-55. PubMed ID: 4989604
    [No Abstract]   [Full Text] [Related]  

  • 19. Sensitivity to Ethambutol and Rifampicin of tubercle bacilli from patients with pulmonary tuberculosis in Sri Lanka.
    Pinto MR; Arseculeratne SN; Dasan P; Uragoda CG
    Ceylon Med J; 1982 Jun; 27(2):75-9. PubMed ID: 6819093
    [No Abstract]   [Full Text] [Related]  

  • 20. [Sensitivity to rifampicin and ethambutol of mycobacteria resistant to isoniazid or streptomycin].
    Golychevskaja VI
    G Ital Chemioter; 1972; 19(2):20-2. PubMed ID: 4199029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.